Evidence map›Paper›PMID 33194767›Full record

ReviewFrontiers in oncology2020

Actors on the Scene: Immune Cells in the Myeloma Niche.

Patrizia Leone, Antonio Giovanni Solimando, Eleonora Malerba, Rossella Fasano, Alessio Buonavoglia, Fabrizio Pappagallo, Valli De Re, Antonella Argentiero, Nicola Silvestris, Angelo Vacca and 1 more

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214324 (Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07214324 recruitingnot on this mapstarted 2025, after this paper: background citation

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

TypeobservationalSponsorAzienda USL Reggio Emilia - IRCCSRan2025 to 2026Enrolled60ConditionsMonoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM)ArmsCollection of biological material
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Patrizia LeoneDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Antonio Giovanni SolimandoDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Eleonora MalerbaDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Rossella FasanoDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Alessio BuonavogliaDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Fabrizio PappagalloDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Valli De ReBio-Proteomics Facility, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Antonella ArgentieroDepartment of Medical Oncology, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, Bari, Italy.
Nicola SilvestrisDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Angelo VaccaDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
Vito RacanelliDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
University of Bari Aldo Moro · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Tumori Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two mechanisms are involved in the immune escape of cancer cells: the immunoediting of tumor cells and the suppression of the immune system. Both processes have been revealed in multiple myeloma (MM). Complex interactions between tumor plasma cells and the bone marrow (BM) microenvironment contribute to generate an immunosuppressive milieu characterized by high concentration of immunosuppressive factors, loss of effective antigen presentation, effector cell dysfunction, and expansion of immunosuppressive cell populations, such as myeloid-derived suppressor cells, regulatory T cells and T cells expressing checkpoint molecules such as programmed cell death 1. Considering the great immunosuppressive impact of BM myeloma microenvironment, many strategies to overcome it and restore myeloma immunosurveillance have been elaborated. The most successful ones are combined approaches such as checkpoint inhibitors in combination with immunomodulatory drugs, anti-monoclonal antibodies, and proteasome inhibitors as well as chimeric antigen receptor (CAR) T cell therapy. How best to combine anti-MM therapies and what is the optimal timing to treat the patient are important questions to be addressed in future trials. Moreover, intratumor MM heterogeneity suggests the crucial importance of tailored therapies to identify patients who might benefit the most from immunotherapy, reaching deeper and more durable responses.

Indexed as

immune cellsimmune checkpointsimmunotherapymicroenvironmentmultiple myeloma

Identifiers

PMID33194767
PMCPMC7658648
OpenAlexW3095540116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.